Session Information

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA18 - Advances in Diagnosis of Common Types of NSCLC

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Tokyo (1982)
    • IASLC CME Accredited
    • Type: Mini Oral Session
    • Track: Pathology
  • +

    MA19 - Looking at PROs in Greater Detail - What Patients Actually Want and Expect

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Interlaken (1988)
    • IASLC CME Accredited
    • Type: Mini Oral Session
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • +

    MA20 - Thymic Tumors: From Molecular to Clinical Results and New Challenges in Other Rare Thoracic Tumors

    • 11:30 - 13:00
    • 9/10/2019
    • Location: San Francisco (2009)
    • IASLC CME Accredited
    • Type: Mini Oral Session
    • Track: Thymoma/Other Thoracic Malignancies
  • +

    MS12 - Genome Screenings

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Vancouver (2003)
    • IASLC CME Accredited
    • Type: Mini Symposium
    • Track: Biology
  • +

    MS13 - Immunotherapy for Mesothelioma

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Seoul (2007)
    • IASLC CME Accredited
    • Type: Mini Symposium
    • Track: Mesothelioma
  • +

    MS14 - Molecular Subsets and Novel Targeted Approaches to Small Cell and Neuroendocrine Cancers

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Colorado Springs (1994)
    • IASLC CME Accredited
    • Type: Mini Symposium
    • Track: Small Cell Lung Cancer/NET
  • +

    MS15 - How to Get Patients to Quit Smoking; Practical Implementation of Evidence-Based Cessation Practices

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Dublin (1997)
    • IASLC CME Accredited
    • Type: Mini Symposium
    • Track: Prevention and Tobacco Control
  • +

    OA13 - Ideal Approach to Lung Resection and Novel Perioperative Therapy

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Toronto (1985)
    • IASLC CME Accredited
    • Type: Oral Session
    • Track: Treatment of Early Stage/Localized Disease
  • +

    OA14 - Update of Phase 3 Trials and the Role of HPD

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Vienna (2016)
    • IASLC CME Accredited
    • Type: Oral Session
    • Track: Immuno-oncology
  • +

    PC04 - Is Chemotherapy Necessary for Advanced NSCLC Patients With PD-L1 50% or More?

    • 11:30 - 13:00
    • 9/10/2019
    • Location: Copenhagen (1980)
    • IASLC CME Accredited
    • Type: Pro-Con Session
    • Track: Advanced NSCLC